Abstract
Despite being covered by Medicare Part D and commercial insurance plans, adoption of SGLT-2 inhibitors has been slower among Black and female patients compared to their White and male counterparts. Additionally, Medicare beneficiaries tend to have lower usage rates compared to those with commercial insurance. This study aims to examine inequalities in SGLT-2 inhibitor use among Medicare patients with type 2 diabetes (T2D), based on demographic and socioeconomic factors and how these factors affect overall Medicare spending.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
